SERA

Sera Prognostics, Inc. [SERA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

SERA Stock Summary

Top 10 Correlated ETFs

SERA

Top 10 Correlated Stocks

SERA

In the News

SERA Financial details

Company Rating
-
Market Cap
303.88M
Income
-35.49M
Revenue
306K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
55
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-4.36
Forward P/E
-
PEG
2.15
P/S
493.79
P/B
2.16
P/C
-
P/FCF
-5.83
Quick Ratio
3.42
Current Ratio
3.51
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.14
EPS next Y
-
EPS next Q
-
EPS this Y
-18.88%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
11.6%
Revenue last 5Y
53.42%
Revenue Q/Q
-2.38%
EPS Q/Q
8.7%
-
-
-
-
SMA20
-25%
SMA50
-25%
SMA100
-57.14%
Inst Own
-
Inst Trans
-
ROA
-41%
ROE
-43%
ROC
-0.54%
Gross Margin
26%
Oper. Margin
-12543%
Profit Margin
-11320%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.52-11.32
52W High
-73.36%
52W Low
+193%
RSI
33
Rel Volume
0.34
Avg Volume
236.8K
Volume
79.78K
Perf Week
-15.8%
Perf Month
-29.23%
Perf Quarter
-61.7%
Perf Half Y
-58.14%
-
-
-
-
Beta
1.494
-
-
Volatility
0.18%, 0.32%
Prev Close
-1.68%
Price
2.93
Change
-2.5%

Something similar

Top by Market Cap
0YXG.L
V
BRK-A
DHR-PB
GOOGL
Top Correlated ETFs
GRI
SOXL
LABU
HYDR
JETS
Top Correlated Stocks
PBFS
5401.T
6363.T
6459.T
7276.T
Similar Market Cap
NAGREEKCAP.NS
ARTNA
IYT
IQQK.DE
SNDL

Company Profile

Healthcare Medical - Diagnostics & Research
  • Volume Average 236.8K
  • Market Capitalization 303.88M
  • Employee 55
  • CEO Ms. Evguenia Lindgardt M.B.A.
  • Headquarters Salt Lake City,UT,US
  • IPO Date 2021-07-15
  • Website https://seraprognostics.com

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.